Incorporated in Ontario, Canada.
Developing FDA pharma-grade, patented & formulated treatments for the international market. 3 Orphan Drugs, 1 lifesaving, planned for Clinical Trials in 2020, preliminary commercialization by 2021.
Exclusive JV and licensing agreements with Israel’s National Medical Cannabis Research Lab at ARO Volcani headed by Professor Hinanit Koltai in Collaboration with Rabin Medical Center, Department of Dermatology, headed by Professor Emilia Hodak.
Consumer products under the brand ELEMENTZ® by MedC Biopharma.
Leishmaniasis development by fully-owned US subsidiary: Dermedy Labs Corporation